REG - Silence Therapeutics - January Conference Schedule

Silence TherapeuticsAnnouncement

05/01/2021 07:01

RNS Number : 5205K
  
Silence Therapeutics PLC
  
05 January 2021
  
 

 
Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences 
 
 
5 January 2021
 
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will participate in a fireside chat at two upcoming investor conferences, details of which can be found below:
 
H.C. Wainwright BioConnect 2021 Conference
 
Date: January 11, 2021
Time: 6:00 a.m. EST (13:00 GMT)
 
ICR Conference 2021
 
Date: Thursday, January 14, 2021
Time: 8:30- 9:10 a.m. EST (13:30 - 14:10 GMT)
 
Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.
 
Enquiries:
 



Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
 
 


Tel:  +1 (646) 637-3208




  Investec Bank plc (Nominated Adviser and Broker) 
Daniel Adams/Gary Clarence
 


  Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




U.S. IR
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com
 


 Tel: +1 (443) 213-0505



 
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCDZGGMLDVGMZM